Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition

Inhibitors of matrix metalloproteinases (MMPs) have been extensively explored to treat pathologies where excessive MMP activity contributes to adverse tissue remodeling. While MMP inhibition remains a relevant therapeutic target, MMP inhibitors have not translated to clinical application due to the dose-limiting side effects following systemic administration of the drugs. Here, we describe the synthesis of a polysaccharide-based hydrogel that can be locally injected into tissues and releases a recombinant tissue inhibitor of MMPs (rTIMP-3) in response to MMP activity. Specifically, rTIMP-3 is sequestered in the hydrogels through electrostatic interactions and is released as crosslinks are degraded by active MMPs. Targeted delivery of the hydrogel/rTIMP-3 construct to regions of MMP over-expression following a myocardial infarction (MI) significantly reduced MMP activity and attenuated adverse left ventricular remodeling in a porcine model of MI. Our findings demonstrate that local, on-demand MMP inhibition is achievable through the use of an injectable and bioresponsive hydrogel.

[1]  J. Burdick,et al.  Experimental and Computational Investigation of Altered Mechanical Properties in Myocardium after Hydrogel Injection , 2013, Annals of Biomedical Engineering.

[2]  K. Healy,et al.  Synthesis and characterization of injectable poly(N-isopropylacrylamide-co-acrylic acid) hydrogels with proteolytically degradable cross-links. , 2003, Biomacromolecules.

[3]  T. Guy,et al.  Region- and Type-Specific Induction of Matrix Metalloproteinases in Post–Myocardial Infarction Remodeling , 2003, Circulation.

[4]  Hai Tian,et al.  TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. , 2007, Journal of molecular and cellular cardiology.

[5]  M. Zile,et al.  Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition , 2003, Circulation.

[6]  J. Peterson.  The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. , 2006, Cardiovascular research.

[7]  Ralph Müller,et al.  Repair of bone defects using synthetic mimetics of collagenous extracellular matrices , 2003, Nature Biotechnology.

[8]  P. Libby,et al.  Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. , 2000, The Journal of clinical investigation.

[9]  R. Khokha,et al.  TIMP-3 Deficiency Leads to Dilated Cardiomyopathy , 2004, Circulation.

[10]  Feng-Huei Lin,et al.  Injectable oxidized hyaluronic acid/adipic acid dihydrazide hydrogel for nucleus pulposus regeneration. , 2010, Acta biomaterialia.

[11]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[12]  B. Fingleton,et al.  Matrix metalloproteinases as valid clinical targets. , 2007, Current pharmaceutical design.

[13]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[14]  A. Metters,et al.  Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Jason A. Burdick,et al.  Hyaluronic Acid Hydrogels for Biomedical Applications , 2011, Advanced materials.

[16]  A. DeMaria,et al.  Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction , 2013, Science Translational Medicine.

[17]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[18]  N. Peppas,et al.  Hydrogels in Pharmaceutical Formulations , 1999 .

[19]  Richard T. Lee,et al.  Local Delivery of Protease-Resistant Stromal Cell Derived Factor-1 for Stem Cell Recruitment After Myocardial Infarction , 2007, Circulation.

[20]  R. Khokha,et al.  Simultaneous Transforming Growth Factor β-Tumor Necrosis Factor Activation and Cross-talk Cause Aberrant Remodeling Response and Myocardial Fibrosis in Timp3-deficient Heart* , 2009, The Journal of Biological Chemistry.

[21]  K. Healy,et al.  Biomimetic matrices for myocardial stabilization and stem cell transplantation. , 2010, Journal of biomedical materials research. Part A.

[22]  B. Mulloy,et al.  Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex , 2012, The Biochemical journal.

[23]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[24]  R. Khokha,et al.  Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. , 1994, The Journal of biological chemistry.

[25]  B. Turk.  Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.

[26]  J. Leor,et al.  The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. , 2011, Biomaterials.

[27]  Andrés J. García,et al.  Bioartificial matrices for therapeutic vascularization , 2009, Proceedings of the National Academy of Sciences.

[28]  Cory E. Leeson,et al.  Extended and sequential delivery of protein from injectable thermoresponsive hydrogels. , 2012, Journal of biomedical materials research. Part A.

[29]  Jason A Burdick,et al.  Moving from static to dynamic complexity in hydrogel design , 2012, Nature Communications.

[30]  F. Spinale,et al.  Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. , 2013, American journal of physiology. Cell physiology.

[31]  D. Fairlie,et al.  Protease inhibitors in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[32]  M. Zile,et al.  Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure: Effects on Left Ventricular Function and Structure , 2003, Circulation research.

[33]  David J Mooney,et al.  Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. , 2007, Cardiovascular research.

[34]  P. Libby,et al.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. , 1999, Circulation.

[35]  Leslie L. Clark,et al.  Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial Infarction: Relation to Left Ventricular Remodeling , 2006, Circulation.

[36]  F. Spinale,et al.  Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging , 2009, Circulation. Heart failure.

[37]  F. Spinale,et al.  A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.

[38]  Xueli Yuan,et al.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.

[39]  Xenophon Papademetris,et al.  Targeted Imaging of the Spatial and Temporal Variation of Matrix Metalloproteinase Activity in a Porcine Model of Postinfarct Remodeling: Relationship to Myocardial Dysfunction , 2011, Circulation. Cardiovascular imaging.

[40]  M. C. Stuart,et al.  Emerging applications of stimuli-responsive polymer materials. , 2010, Nature materials.

[41]  Linda Troeberg,et al.  Proteases involved in cartilage matrix degradation in osteoarthritis. , 2012, Biochimica et biophysica acta.

[42]  M. Zile,et al.  Integrating the myocardial matrix into heart failure recognition and management. , 2013, Circulation research.

[43]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[44]  L. Peek,et al.  Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor. , 2007, Biomacromolecules.

[45]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[46]  Christine N. Koval,et al.  Dynamic Changes in Matrix Metalloprotienase Activity Within the Human Myocardial Interstitium During Myocardial Arrest and Reperfusion , 2008, Circulation.

[47]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[48]  Jeffrey A. Hubbell,et al.  Polymeric biomaterials with degradation sites for proteases involved in cell migration , 1999 .

[49]  B. Strauss,et al.  Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. , 2003, American journal of physiology. Heart and circulatory physiology.

[50]  G. Murphy,et al.  Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1* , 2007, Journal of Biological Chemistry.

[51]  Robert C Gorman,et al.  Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model , 2010, Proceedings of the National Academy of Sciences.